180 Life Sciences

ATNFPhase 3

180 Life Sciences is pioneering new approaches to treating inflammatory and fibrotic diseases through a diversified pipeline of clinical and pre-clinical programs. Its core strategy involves repurposing and optimizing anti-TNF therapies for localized fibrotic conditions and exploring synthetic cannabinoids for pain and inflammation. The company faces the challenges typical of a clinical-stage biotech but is led by a team with deep experience in drug development and immunology.

Market Cap

$21.6M

Employees

1-10

Focus

Biotech

AI Company Overview

Technology Platform

Expertise in localized anti-TNF therapy for fibrosis and development of novel synthetic cannabinoid analogs designed to separate therapeutic benefits from psychoactive effects.

Pipeline Snapshot

1 drug in pipeline, 1 in Phase 3

Drug	Indication	Stage
Adalimumab Injection + Placebo	Frozen Shoulder	Phase 2/3

Opportunities

Major opportunity lies in being first-to-market with an injectable pharmacological therapy for Dupuytren's disease and frozen shoulder, potentially capturing a multi-billion dollar market currently served only by surgery.

Success could also validate the localized anti-TNF platform for other fibrotic conditions.

The cannabinoid program offers a potential entry into the large and growing non-opioid pain management market.

Risk Factors

High risk of clinical trial failure for lead programs.

Limited cash runway necessitates dilutive financing.

Faces regulatory uncertainty for novel treatments in fibrosis.

As a micro-cap stock, it is highly volatile and sensitive to market sentiment.

Competitive Landscape

Faces limited direct pharmaceutical competition in localized fibrosis, competing primarily against surgical procedures. Differentiates via targeted anti-TNF delivery to avoid systemic side effects. In cannabinoids, competes in a crowded field where differentiation will depend on clinical profile of its novel synthetic analogs.